XORTX Therapeutics acquires Vectus Biosystems

XORTX Therapeutics agreed to acquire Vectus Biosystems. Reported deal value: $3M. Status: Pending. Sector: Pharmaceutical. Target headquarters context: Rosebery, New South Wales, Australia.

This page summarizes publicly available information about the transaction as of 2026-02-05. Figures and status may change as filings and press coverage update.

XORTX Therapeutics Inc. , a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that further to its press release of October 17, 2025 and an update on December 31 , 2025, the Company has entered into an extension agreement with Vectus Biosystems Limited to allow further time to complete the acquisition of the Renal Anti - Fibrotic Therapeutic Program from Vectus